Bristol-Myers Squibb Company (BMY)

54.57
0.33 0.61
NYSE : Health Care
Prev Close 54.24
Open 54.22
Day Low/High 53.94 / 54.75
52 Wk Low/High 46.01 / 76.48
Volume 2.13M
Avg Volume 7.38M
Exchange NYSE
Shares Outstanding 1.65B
Market Cap 92.22B
EPS 2.70
P/E Ratio 19.44
Div & Yield 1.56 (2.80%)

Latest News

Nasdaq Tumbles as Tech Takes a Turn Lower

Nasdaq Tumbles as Tech Takes a Turn Lower

The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.

Wall Street Trades at Records as Facebook Rallies

Wall Street Trades at Records as Facebook Rallies

Stocks are higher.

Stock Futures Power Higher on Earnings Beat From Facebook

Stock Futures Power Higher on Earnings Beat From Facebook

Stock futures are higher.

Facebook on Fire - 5 Things You Must Know Before the Market Opens Thursday

Facebook on Fire - 5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures point higher after Facebook shares jump.

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2017 which were highlighted by strong sales for key products Opdivo and Eliquis and regulatory approvals for Opdivo, the...

Bristol-Myers Squibb's ORENCIA® (abatacept) Receives Second European Commission Approval In Less Than A Year - New Approval For Treatment Of Active Psoriatic Arthritis (PsA)1

Bristol-Myers Squibb's ORENCIA® (abatacept) Receives Second European Commission Approval In Less Than A Year - New Approval For Treatment Of Active Psoriatic Arthritis (PsA)1

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission (EC) has approved ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis (PsA) in adult...

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

Amazon Snags Former Box Executive of Health In Pursuit of the Medical Industry

Amazon Snags Former Box Executive of Health In Pursuit of the Medical Industry

Amazon has been reinforcing its HIPAA-compliant offerings so that health-care providers and insurers can save and transfer customer data.

Market Can Rally Again … Can't It?

Non-FANG stocks aren't looking too sharp.

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

My three top predictions for the next six months.

Biotech Movers: Exelixis, Omeros, Inovio

Biotech Movers: Exelixis, Omeros, Inovio

Exelixis, Omeros and Inovio Pharmaceuticals were among the biotech movers in premarket trading on July 10.

Summer Watch List: How Some Key Names Are Stacking Up

Here's what to focus on from these stocks in July.

Exelixis And Bristol-Myers Squibb Initiate Phase 3 Trial Of Opdivo® In Combination With CABOMETYX™ Or Opdivo And Yervoy® In Combination With CABOMETYX, Versus Sunitinib In Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Exelixis And Bristol-Myers Squibb Initiate Phase 3 Trial Of Opdivo® In Combination With CABOMETYX™ Or Opdivo And Yervoy® In Combination With CABOMETYX, Versus Sunitinib In Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the initiation of the phase 3 CheckMate 9ER trial to evaluate Opdivo ® (nivolumab) in combination with CABOMETYX™...

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.

Bristol Myers Vies to Be King of Immune-Boosting Cancer Drugs with New Trial Update

Bristol Myers Vies to Be King of Immune-Boosting Cancer Drugs with New Trial Update

The trial's success props open doors for exploring new uses for Opdivo's treatment in immunotherapy.

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval For Treatment Of Active Psoriatic Arthritis (PsA) In Adults

Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval For Treatment Of Active Psoriatic Arthritis (PsA) In Adults

Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.

Keep Your Eyes on the Bonds

Is this just a retest or a new leg down?

Intermediate Trade: Bristol-Myers Squibb

Intermediate Trade: Bristol-Myers Squibb

The trade is the out-of-the-money, bullishly biased vertical call spread expiring in August.

Phase 3 Study Evaluating the Safety And Efficacy Of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

Phase 3 Study Evaluating the Safety And Efficacy Of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

Bristol-Myers Squibb Company (NYSE:BMY) announced today that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of...

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

Ready. Raise. Rise. Spokespeople Tia Mowry, Eric Stonestreet And Dak Prescott (Photo: Business Wire)

Eric Stonestreet of television's hit comedy "Modern Family" and new reality competition series, "The Toy Box," is once again lending his star power to the Ready.

Four-Year Follow-up With Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) In Patients With Advanced Multiple Myeloma Shows Long-term Efficacy In ELOQUENT-2 Trial

Bristol-Myers Squibb Company (NYSE:BMY) presented four-year follow-up data from the Phase 3 ELOQUENT-2 study in which Empliciti (elotuzumab) plus lenalidomide/dexamethasone (ELd) continued to demonstrate efficacy in...